We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unveiling Ashland (ASH) Q4 Outlook: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
In its upcoming report, Ashland (ASH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.33 per share, reflecting an increase of 224.4% compared to the same period last year. Revenues are forecasted to be $518.74 million, representing a year-over-year increase of 0.1%.
The consensus EPS estimate for the quarter has undergone a downward revision of 3.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain Ashland metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts' assessment points toward 'Revenue- Intermediates' reaching $34.09 million. The estimate indicates a year-over-year change of -7.9%.
The consensus estimate for 'Revenue- Specialty Additives' stands at $139.74 million. The estimate points to a change of -3% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenue- Personal Care' should come in at $173.70 million. The estimate points to a change of +19% from the year-ago quarter.
Analysts predict that the 'Revenue- Life Sciences' will reach $182.52 million. The estimate indicates a year-over-year change of -10.1%.
Based on the collective assessment of analysts, 'Adjusted EBITDA- Intermediates' should arrive at $9.02 million. The estimate compares to the year-ago value of $3 million.
Analysts forecast 'Adjusted EBITDA- Personal Care' to reach $48.15 million. The estimate compares to the year-ago value of $36 million.
Ashland shares have witnessed a change of +1% in the past month, in contrast to the Zacks S&P 500 composite's -0.5% move. With a Zacks Rank #4 (Sell), ASH is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unveiling Ashland (ASH) Q4 Outlook: Wall Street Estimates for Key Metrics
In its upcoming report, Ashland (ASH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.33 per share, reflecting an increase of 224.4% compared to the same period last year. Revenues are forecasted to be $518.74 million, representing a year-over-year increase of 0.1%.
The consensus EPS estimate for the quarter has undergone a downward revision of 3.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
In light of this perspective, let's dive into the average estimates of certain Ashland metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts' assessment points toward 'Revenue- Intermediates' reaching $34.09 million. The estimate indicates a year-over-year change of -7.9%.
The consensus estimate for 'Revenue- Specialty Additives' stands at $139.74 million. The estimate points to a change of -3% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenue- Personal Care' should come in at $173.70 million. The estimate points to a change of +19% from the year-ago quarter.
Analysts predict that the 'Revenue- Life Sciences' will reach $182.52 million. The estimate indicates a year-over-year change of -10.1%.
Based on the collective assessment of analysts, 'Adjusted EBITDA- Intermediates' should arrive at $9.02 million. The estimate compares to the year-ago value of $3 million.
Analysts forecast 'Adjusted EBITDA- Personal Care' to reach $48.15 million. The estimate compares to the year-ago value of $36 million.
View all Key Company Metrics for Ashland here>>>
Ashland shares have witnessed a change of +1% in the past month, in contrast to the Zacks S&P 500 composite's -0.5% move. With a Zacks Rank #4 (Sell), ASH is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>